Press releases
- Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
- Precision BioSciences Receives Initial $7.5 Million Cash Payment and Equity Investment from TG Therapeutics for Azel-Cel in Treatment of Autoimmune Diseases
- Precision BioSciences Completes License Deal with TG Therapeutics for Cell Therapy Azer-Cel in Treatment of Autoimmune Diseases
Key statistics
On Thursday, TG Therapeutics Inc (NKB2:MUN) closed at 14.37, 124.67% above the 52 week low of 6.40 set on Oct 24, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 14.37 |
---|---|
High | 14.37 |
Low | 14.37 |
Bid | -- |
Offer | -- |
Previous close | 14.37 |
Average volume | 2.44 |
---|---|
Shares outstanding | 154.42m |
Free float | 140.40m |
P/E (TTM) | 1,102.69 |
Market cap | 2.40bn USD |
EPS (TTM) | 0.0141 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 07:05 BST.
More ▼